Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy.
drug delivery system (DDS)
imaging
nuclear localization signal (NLS)
radiolabeled antibody
targeted alpha therapy (TAT)
α-ray
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
25
04
2023
revised:
15
05
2023
accepted:
30
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Targeted alpha therapy (TAT) has garnered significant interest as an innovative cancer therapy. Owing to their high energy and short range, achieving selective α-particle accumulation in target tumor cells is crucial for obtaining high potency without adverse effects. To meet this demand, we fabricated an innovative radiolabeled antibody, specifically designed to selectively deliver
Identifiants
pubmed: 37298546
pii: ijms24119593
doi: 10.3390/ijms24119593
pmc: PMC10253442
pii:
doi:
Substances chimiques
Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20H05675
Organisme : Japan Society for the Promotion of Science
ID : 20K05727
Organisme : Japan Society for the Promotion of Science
ID : 21H05074
Organisme : Japan Science and Technology Agency
ID : JPMJCR20R3
Organisme : Japan Agency for Medical Research and Development
ID : 20ek0109444h0001
Organisme : Japan Agency for Medical Research and Development
ID : 20fk0210079h0001
Organisme : Japan Science and Technology Agency
ID : JPMJFR211Z
Références
Cell. 1984 Dec;39(3 Pt 2):499-509
pubmed: 6096007
Cancer Sci. 2017 Aug;108(8):1648-1656
pubmed: 28514062
Front Med (Lausanne). 2021 Jul 27;8:692436
pubmed: 34386508
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Cancer Sci. 2021 Mar;112(3):1132-1140
pubmed: 33277750
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
Mol Cancer Res. 2020 Jan;18(1):3-19
pubmed: 31659006
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):849-858
pubmed: 36344651
ACS Chem Biol. 2011 Dec 16;6(12):1332-8
pubmed: 21977972
Clin Cancer Res. 1996 Mar;2(3):457-70
pubmed: 9816191
Nat Cell Biol. 2009 Feb;11(2):162-71
pubmed: 19136966
Angew Chem Int Ed Engl. 2018 Oct 22;57(43):13968-13981
pubmed: 29992706
Bioconjug Chem. 2007 Jul-Aug;18(4):1226-40
pubmed: 17583925
J Nucl Med. 2019 Sep;60(9):1301-1307
pubmed: 30796173
Pharmaceutics. 2020 Dec 31;13(1):
pubmed: 33396374
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Int J Oncol. 2015 Mar;46(3):1099-108
pubmed: 25502497
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Cancers (Basel). 2022 Mar 11;14(6):
pubmed: 35326605
Bioconjug Chem. 2002 Jul-Aug;13(4):855-69
pubmed: 12121142
Bioconjug Chem. 2012 Mar 21;23(3):409-20
pubmed: 22296587
Lancet. 2019 Aug 31;394(10200):793-804
pubmed: 31478503
Angew Chem Int Ed Engl. 2019 Oct 28;58(44):15584-15594
pubmed: 31237741
N Engl J Med. 2005 Feb 3;352(5):441-9
pubmed: 15689582
Nature. 2022 Mar;603(7902):637-642
pubmed: 35322251
Pharmaceutics. 2022 Dec 02;14(12):
pubmed: 36559199
Bioconjug Chem. 2009 Mar 18;20(3):591-602
pubmed: 19236022
Sci Rep. 2021 Jun 21;11(1):12982
pubmed: 34155314
Chem Sci. 2018 Dec 21;10(7):1936-1944
pubmed: 30881623